Long-term treatment outcomes in Gaucher disease (Q38533851)

3 September 2017

1 reference

title

Long-term treatment outcomes in Gaucher disease (English)

1 reference

3 September 2017

1 reference

Joel Charrow

1

1 reference

PubMed ID

26096742

3 September 2017

C Ronald Scott

series ordinal

2

1 reference

3 September 2017

1 July 2015

1 reference

American Journal of Hematology

3 September 2017

1 reference

3 September 2017

90 Suppl 1

1 reference

3 September 2017

S19-24

1 reference

Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease

3 September 2017

1 reference

Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment

21 January 2018

1 reference

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

21 January 2018

1 reference

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

21 January 2018

1 reference

The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.

21 January 2018

1 reference

Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis

21 January 2018

1 reference

Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.

21 January 2018

1 reference

Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults

21 January 2018

1 reference

Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients

21 January 2018

1 reference

Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

21 January 2018

1 reference

21 January 2018

1 reference

Quality of life assessment in adults with type 1 Gaucher disease.

21 January 2018

1 reference

Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.

21 January 2018

1 reference

Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.

21 January 2018

1 reference

Therapeutic goals in the treatment of Gaucher disease.

21 January 2018

1 reference

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase

21 January 2018

1 reference

Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry

21 January 2018

1 reference

Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

21 January 2018

1 reference

Randomized, controlled trial of miglustat in Gaucher's disease type 3.

21 January 2018

1 reference

Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III.

21 January 2018

1 reference

Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years

21 January 2018

1 reference

Cessation of enzyme replacement therapy in Gaucher disease

21 January 2018

1 reference

Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease

21 January 2018

1 reference

Gaucher disease and cancer incidence: a study from the Gaucher Registry.

21 January 2018

1 reference

The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.24056

1 reference

3 September 2017

1 reference

PubMed ID

26096742